Contribute Try STAT+ Today

As anticipation builds over the arrival of safe and effective Covid-19 vaccines, a growing challenge for the various manufacturers is to plot a successful path for distribution. The issues range from ensuring vaccines are stored at necessary temperatures and expanding manufacturing capacity to preventing theft and making deliveries in countries where infrastructure is lacking. One of the people responsible for piecing together such public health jigsaw puzzles is Remo Colarusso, vice president for supply chain responsibilities at Janssen, a Johnson & Johnson (JNJ) subsidiary that is among the companies racing to develop a vaccine. We spoke with him about the effort and how the company is approaching the task. This is an edited version of our conversation. 

Before we get into distribution, what’s the status of your vaccine?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.